

Pharmacy Formulary Updates for August 2024

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in August 2024:

| Drug Name | Tufts Health Public Plan Formulary |
|---------------------------|------------------------------------|
| | Tufts Health Direct Formulary |
| Duvyzat | NF;QL |
| Filsuvez | T3;PA;QL |
| Folic acid 0.4 mg, 0.8 mg | T1 |
| Ingrezza Sprinkle | T3;PA;QL |
| Libervant | NF |
| Rextovy | \$0;QL |
| Rezdiffra | T3;PA;QL;SPP |
| Rinvoq LQ | T3;PA;QL;SPP |
| Vijoice | T3;PA;SPP |